Treatment of hepatitis C virus infections with interleukin-10
AssigneeSchering Corporation
InventorsPaul C. Grint, David R. Nelson, Gary L. Davis
Life of this patent
Estimating the term…
Abstract
The hepatoprotective effect of IL-10 is described, in particular, the use of interleukin-10 in the treatment of liver damage (e.g. fibrosis or cirrhosis) in a difficult-to-treat patient afflicted with chronic hepatitis C virus infection who has failed to respond to, or achieve a sustained virologic response to an anti-HCV therapy(e.g., interferon-α in combination with ribavirin).
Claims12
A method for improving liver histology in a patient afflicted with a chronic hepatitis C virus (“HCV”) infection comprising administering an effective amount of an interleukin-10 to a patient afflicted with chronic HCV infection who has failed to achieve a sustained virologic response after treatment with any type of anti-HCV therapy comprising interferon-α or pegylated interferon-α alone, or interferon-α or pegylated interferon-α in combination with ribavirin.
A method for treating hepatic fibrosis in a patient afflicted with a chronic hepatitis C virus (“HCV”) infection comprising administering an effective amount of an interleukin-10 to a patient afflicted with chronic HCV infection who has failed to achieve a sustained virologic response after treatment with any type of anti-HCV therapy comprising interferon-α or pegylated interferon-α alone, or interferon-α or pegylated interferon-α in combination with ribavirin.
A method for modulating the inflammatory response of a patient afflicted with a chronic hepatitis C virus (“HCV”) infection comprising administering an effective amount of an interleukin-10 to a patient afflicted with chronic HCV infection who has failed to achieve a sustained virologic response after treatment with any type of anti-HCV therapy comprising interferon-α or pegylated interferon-α alone, or interferon-α or pegylated interferon-α in combination with ribavirin.
Dependencies are inferred from the claim text.